A first-of-its-kind Parkinson's pill cut daily 'off time' in a 341-person Phase 3 trial

For the million Americans living with Parkinson's, the hours when medication wears off and movement freezes are among the hardest parts of the day. Cerevance reported that its once-daily pill solengepras — which works through a brain receptor never targeted before, instead of the usual dopamine route — reduced daily off time by an extra 37 minutes versus placebo in a 341-person Phase 3 trial, while also easing daytime sleepiness and improving quality of life. The results were presented at the 2026 International Congress of Parkinson's Disease and Movement Disorders in Seoul.